Affordable Access

Access to the full text

Sustained Erythroid Response in a Patient with Myelofibrosis Receiving Concomitant Treatment with Ruxolitinib and Deferasirox

Authors
  • Piro, Eugenio
  • Lentini, Maria
  • Levato, Luciano
  • Russo, Antonio
  • Molica, Stefano
Type
Published Article
Journal
Chemotherapy
Publisher
S. Karger AG
Publication Date
Apr 25, 2018
Volume
63
Issue
2
Pages
107–110
Identifiers
DOI: 10.1159/000486822
PMID: 29694973
Source
Karger
Keywords
License
Green
External links

Abstract

Iron overload (IOL) due to transfusion-dependent anemia is a serious adverse effect in patients with myelofibrosis (MF). Recent studies have shown that the oral iron chelator deferasirox may prevent multiple organ damage due to IOL in MF. However, it is not clear whether deferasirox may contribute to revert transfusion-dependent anemia. Here, we present a patient with transfusion-dependent intermediate-2 MF according to the International Prognostic Scoring System treated with ruxolitinib in combination with deferasirox. In addition to a reduced serum ferritin level, the patient required less blood transfusions, ultimately resulting in long-lasting transfusion-free survival.

Report this publication

Statistics

Seen <100 times